Royce & Associates LP Blueprint Medicines Corp Transaction History
Royce & Associates LP
- $8.75 Billion
- Q1 2025
A detailed history of Royce & Associates LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Royce & Associates LP holds 18,001 shares of BPMC stock, worth $1.83 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
18,001Holding current value
$1.83 Million% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
394Shares Held
60.4MCall Options Held
1.6MPut Options Held
1.41M-
Black Rock Inc. New York, NY6.65MShares$677 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$676 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$578 Million0.06% of portfolio
-
State Street Corp Boston, MA2.5MShares$255 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.49MShares$152 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.08B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...